Pharma BD Deal Intelligence

AstraZeneca PLC / Almirall S.A. (respiratory franchise)

2014 · Asset Purchase · $2.1B · Complete

Announcement Sentiment

Neutral / mixed

AstraZeneca agreed to acquire Almirall's respiratory business including Eklira/Tudorza and the Genuair device for $875M upfront plus up to $1.22B in development/launch/sales milestones. Strengthened AstraZeneca's COPD/asthma portfolio alongside Symbicort and Pulmicort; closed November 3, 2014.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Neutral

Pipeline outcome

Mixed

Assessment window: 10yr post-close.

Key facts

Announced Jul 30, 2014
Closed Nov 03, 2014
Deal value $2.1B
Deal type Asset Purchase
Therapeutic area COPD and asthma
Indications COPD and asthma
Key assets Eklira/Tudorza (aclidinium), aclidinium/formoterol fixed-dose combo, Genuair device platform
Mechanism Long-acting muscarinic antagonist (LAMA) and LAMA/LABA fixed-dose combinations

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals